The laureate professor at the University of Melbourne detailed the design and promising results of the PACIFIC trial of bexicaserin, an agent in development for epileptic encephalopathies. [WATCH TIME: 4 minutes]
Ingrid Scheffer, AO, PhD, FRACP, FAHMS, FAA
Advertisement
Articles by Ingrid Scheffer, AO, PhD, FRACP, FAHMS, FAA
Advertisement
Latest Updated Articles
Overviewing Phase 1/2 PACIFIC Trial of Bexicaserin in Developmental Epileptic Encephalopathies: Ingrid Scheffer, AO, PhD, FRACP, FAHMS, FAAPublished: September 4th 2025 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Enhancing Stroke Systems of Care
2
FDA Fast Tracks Etalanetug, Encouraging Interim TEMPO-4 Data, Initial Data on Cell Therapy UX-DA001
3
Incidence and Prevalence of Frontotemporal Dementia Similar to Dementia with Lewy Bodies, Meta-Analysis Shows
4
Benzodiazepines and Antipsychotics Tied to Higher Mortality in Hospice Patients With Dementia
5
